FDA Outlines Systems Manufacturers Should Have In Place For Handling Suspect Drugs Under DSCSA
Executive Summary
Manufacturers need to have robust verification processes in place and actively communicate with their trading partners to handle suspect drugs that are not properly serialized under DSCA, FDA draft guidance document says.
You may also be interested in...
The Quality Lowdown: DSCSA, Recalls, Extractables & Leachables And Nitrosamines
The US FDA refines guidance on verification systems for suspect drug products and voluntary recalls, while industry groups issue guidance on extractables and leachables in parenteral drugs and the role of excipients in nitrosamine formation.
Industry Groups Seek More Options In Responding To DSCSA Verification Requests
PhRMA and AAM suggest the US FDA should give pharmaceutical manufacturers more time to respond to requests from trading partners to verify that suspect and illegitimate products had been received. They point out that while DSCSA requires responses to verification requests be made within 24 hours, the law allows FDA to make exceptions.
Pharmaceutical Manufacturers Testing Use of Verification Router Services To Process Saleable Returns Under DSCSA
Pharmaceutical manufacturers, distributors and wholesalers are piloting the use of verification router service (VRS) systems to comply with a looming deadline under DSCSA requiring them to establish systems for verifying saleable returns. Yet there are still many unanswered questions on how these systems will work.